Four years ago, protein drug developer Zymogenetics in Seattle began developing a recombinant version of the blood-clotting protein thrombin. On 17 January, it received US marketing approval for ...

In March 2008, the European Commission granted marketing authorization for dabigatran etexilate (Pradaxa; Boehringer Ingelheim), a direct thrombin inhibitor, for the prevention of venous ...

Antithrombin, a plasma protein, has been reported to control thrombin activity by directly binding to thrombin, as well as to have an anti-inflammatory effect. However, the actual molecular ...